A

AnaptysBio
D

ANAB

13.950
USD
-0.62
(-4.26%)
Market Closed
Volume
20,130
EPS
-6
Div Yield
-
P/E
-2
Market Cap
424,480,114
OverviewSignalsIdeasNews
Related Instruments
    A
    ACAD
    0.320
    (1.90%)
    17.200 USD
    ALNY
    ALNY
    -3.355
    (-1.37%)
    242.150 USD
    C
    CRSP
    -0.220
    (-0.54%)
    40.500 USD
    E
    ESPR
    0.05000
    (2.29%)
    2.23000 USD
    N
    NBIX
    1.590
    (1.17%)
    137.050 USD
    REGN
    REGN
    12.38
    (1.76%)
    714.98 USD
    S
    SRPT
    1.570
    (1.32%)
    120.540 USD
    V
    VKTX
    0.045
    (0.11%)
    42.315 USD
    X
    XLRN
    0
    (0%)
    0.000000 USD
    More
News

Title: AnaptysBio

Sector: Healthcare
Industry: Biotechnology
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA)and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).